Remove 2026 Remove Compounding Remove Drug Development
article thumbnail

Sionna Therapeutics secures $182m for cystic fibrosis drug development

Pharmaceutical Business Review

Additionally, Sionna is progressing with the development of compounds targeting complementary mechanisms. This capital raise provides financial flexibility positioning us to execute our clinical development plan with funding through 2026 and multiple value-creating clinical readouts.”

article thumbnail

Biopharmaceutical bioseparation systems market to value $20bn

European Pharmaceutical Review

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods. percent CAGR between 2022 and 2026.

Dosage 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SMi’s 22nd Annual Pain Therapeutics Conference

pharmaphorum

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Analgesic pre-clinical development. Drug development. Exploratory development. Sponsored by: CHDR. Million in 2018 and is projected to reach USD 15.87

article thumbnail

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.

article thumbnail

Orphan drugs’ financial success raises questions

pharmaphorum

Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ This is based on the relative success orphan drugs have achieved, in terms of the number of approvals and the sales figures achieved for this area.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. A first priority is clarifying how providers should submit claims for drugs subject to the MFP.

article thumbnail

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmaTech

The LNP-encapsulated small interfering RNA (siRNA) was approved by FDA for the treatment of hereditary transthyretin amyloidosis (ATTR), and this opened the door for mRNA-based drugs in many applications. It is also developing BNT165e, an RNA-based vaccine for the prevention of P. falciparum malaria. during 2025–2034 (26).